Carregant...
Bortezomib decreases the magnitude of a primary humoral immune response to transfused RBCs in a murine model
BACKGROUND: Few therapeutic options currently exist to prevent or to mitigate transfusion associated RBC alloimmunization. We hypothesized that bortezomib, a proteasome inhibitor currently being utilized for HLA alloantibody and ADAMTS13 autoantibody reduction, may be beneficial in a transfusion set...
Guardat en:
| Publicat a: | Transfusion |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5559200/ https://ncbi.nlm.nih.gov/pubmed/27734515 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/trf.13864 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|